Opdualag
| Chemical Name | nivolumab and relatlimab-rmbw |
| Dosage Form | Injection (intravenous; 240 mg of nivolumab and 80 mg of relatlimab per 20 mL (12 mg and 4 mg per mL)) |
| Drug Class | Monoclonal antibodies |
| System | Skin |
| Company | Bristol-Myers Squibb |
| Approval Year | 2022 |
Indication
- For the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma